An Insight into Coronavirus Disease 2019 in Patients with Pre-Existing Viral Hepatitis
Abstract
Keywords
Full Text:
Download PDFReferences
Parvez MK, Jagirdar RM, Purty RS, et al., 2020, COVID-19 Pandemic: Understanding the Emergence, Pathogenesis and Containment. World Acad Sci J, 2:18. DOI: 10.3892/ wasj.2020.59.
Parvez MK, Padhan K, 2021, Current Advances in Novel SARS-CoV-2 Disease Treatment and Intervention Strategies. Coronaviruses, 2:1–6. DOI: 10.2174/26667967 01999201116125249.
Parvez MK, 2020, COVID-19 and Coronaviral Hepatitis: Evidence of Collateral Damage. Future Virol, 6:325–9. DOI: 10.2217/fvl-2020-0065.
Chen X, Jiang Q, Ma Z, et al., 2020, Clinical Characteristics of Hospitalized Patients with SARS-CoV-2 and Hepatitis B Virus Co-infection. Virol Sin, 35:842–5. DOI: 10.1007/ s12250-020-00276-5.
Wu J, Yu J, Shi X, et al., 2021, Epidemiological and Clinical Characteristics of 70 Cases of Coronavirus Disease and Concomitant Hepatitis B Virus Infection: A Multicentre Descriptive Study. J Viral Hepat, 28:80–8. DOI: 10.1111/ jvh.13404.
Liu J, Wang T, Cai Q, et al., 2020, Longitudinal Changes of Liver Function and Hepatitis B Reactivation in COVID-19 Patients with Pre-existing Chronic Hepatitis B Virus Infection. Hepatol Res, 50:1211–21. DOI: 10.1111/ hepr.13553.
Aldhaleei WA, Alnuaimi A, Bhagavathula AS, 2020, COVID-19 Induced Hepatitis B Virus Reactivation: A Novel Case from the United Arab Emirates. Cureus, 12:e8645. DOI: 10.7759/cureus.8645.
Richardson S, Hirsch JS, Narasimhan M, et al., 2020, Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID‐19 in the New York city area. JAMA, 323:2052–9. DOI: 10.3410/f.737797860.793574198.
Chen L, Huang S, Yang J, et al., 2020, Clinical Characteristics in Patients with SARS-CoV-2/HBV Coinfection. J Viral Hepat, 27:1504–7.
He Q, Zhang G, Gu Y, et al., 2020, Clinical Characteristics of COVID-19 Patients with Pre-existing Hepatitis B Virus Infection: A Multicenter Report. Am J Gastroenterol, 116:420–1.
Zhang B, Huang W, Zhang S, 2020, Clinical Features and Outcomes of Coronavirus Disease 2019 (COVID-19) Patients with Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol, 18:2633–7. DOI: 10.1016/j.cgh.2020.06.011.
Yu R, Tan S, Dan Y, et al., 2021, Effect of SARS-CoV-2 Coinfection was not Apparent on the Dynamics of Chronic Hepatitis B Infection. Virology, 553:131–4. DOI: 10.1016/j. virol.2020.11.012.
Zhao J, Liao X, Wang H, et al., 2020, Early Virus Clearance and Delayed Antibody Response in a Case of COVID-19 with a History of Co-infection with HIV-1 and HCV. Clin Infect, 72:180–2.
Rodríguez-Tajes S, Miralpeix A, Costa J, et al., 2021, Low Risk of Hepatitis B Reactivation in Patients with Severe COVID-19 who Receive Immunosuppressive Therapy. J Viral Hepat, 28:89–94. DOI: 10.1111/jvh.13410.
Zha L, Li S, Pan L, et al., 2020, Corticosteroid Treatment of Patients with Coronavirus Disease (COVID‐19). Med J Australia, 212:416–20.
Reddy KR, Beavers KL, Hammond SP, et al., 2015. American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation during Immunosuppressive Drug Therapy. Gastroenterology, 148:215–9. DOI: 10.1053/j. gastro.2014.10.039.
DOI: http://dx.doi.org/10.18063/ghl.v3i1.266
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Parvez

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Recent Articles | About Journal | For Author | Fees | About Whioce
Copyright © Whioce Publishing Pte Ltd. All Rights Reserved.